adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
pharma · Molluscum Contagiosum · Common Warts (Verruca Vulgaris) · VRCA
Verrica Pharmaceuticals
Verrica Pharmaceuticals drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
West Chester, USA HQ
2013 Founded
80 Employees
Public company Type
VRCA · NYSE Ticker
Company details
- Status
- Public
- HQ
- West Chester, USA
- Founded
- 2013
- Employees
- 80
- Programs
- 7
- Drugs
- 3
- Patents
- 7
Verrica Pharmaceuticals pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Verrica Pharmaceuticals drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
Development asset linked to Verrica Pharmaceuticals in public FDA and regional records.